Today’s Research Reports on Trending Tickers: Zogenix and Momenta Pharmaceuticals
U.S. equities closed up on Friday and posted its 2nd consecutive weekly gain, as investors continue to focus on a strong start to the earnings season. While the Dow reclaimed its above 25,000 levels after almost a month Nasdaq is at a record high. The Dow Jones Industrial Average gained 0.38 percent to close at 25,019.41, while the S&P 500 Index increased 0.11 percent to close at 2,801.31. The Nasdaq Composite Index climbed 0.03 percent to close at 7,825.98. For the week, the Dow Jones hiked 2.3 percent, while the S&P 500 jumped 1.5 percent, and the Nasdaq finished 1.8 percent higher.
According to Anthony Saglimbene, global market strategist at Ameriprise Financial, “We’re pretty positive on the overall market; the 20% profit growth we’re expecting this quarter should be a fundamental anchor for stocks. But while financials have a good outlook, the results we saw today were mixed and the sector’s growth will probably underperform the S&P 500 this quarter.”
RDI Initiates Coverage on:
Momenta Pharmaceuticals, Inc.
Zogenix’s stock jumped 9.75% Friday, to close the day at $61.35. The stock recorded a trading volume of 3,150,808 shares, which was above its three months average volume of 552,376 shares. In the last year, Zogenix’s shares have traded in a range of 10.05 – 62.75. The share price has gained 510.45% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $42.98 is above its 200-day moving average of $40.35. Shares of Zogenix have gained roughly 36.33 percent in the past month and are up 53.18 percent year-to-date.
Access RDI’s Zogenix, Inc. Research Report at:
On Friday, shares of Momenta Pharmaceuticals recorded a trading volume of 1,026,474 shares, which was above the three months average volume of 574,428 shares. The stock ended the day 6.26% higher at $28.00. The share price has fallen 1.75% from its 52 week high with a 52 week trading range of 11.85 – 28.50. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $22.81 is above its 200-day moving average of $18.66. Shares of Momenta Pharmaceuticals have gained roughly 27.85 percent in the past month and are up 100.72 percent year-to-date.
Access RDI’s Momenta Pharmaceuticals, Inc. Research Report at:
Our Actionable Research on Zogenix, Inc. (NASDAQ:ZGNX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.